Found: 7
Select item for more details and to access through your institution.
Food and Drug Administration Public Workshop Summary—Addressing Challenges in Inhaled Antifungal Drug Development.
- Published in:
- Clinical Infectious Diseases, 2024, v. 78, n. 6, p. 1564, doi. 10.1093/cid/ciad607
- By:
- Publication type:
- Article
Reply to White et al.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Effect of Body Weight and Age on the Pharmacokinetics of Dihydroartemisinin: Food and Drug Administration Basis for Dose Determination of Artesunate for Injection in Pediatric Patients With Severe Malaria.
- Published in:
- Clinical Infectious Diseases, 2021, v. 73, n. 5, p. 903, doi. 10.1093/cid/ciab149
- By:
- Publication type:
- Article
Regulatory Considerations in the Approval of Rezafungin (Rezzayo) for the Treatment of Candidemia and Invasive Candidiasis in Adults.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 2, p. 505, doi. 10.1093/infdis/jiae146
- By:
- Publication type:
- Article
Rhesus θ-Defensin-1 Attenuates Endotoxin-induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment.
- Published in:
- American Journal of Respiratory Cell & Molecular Biology, 2018, v. 58, n. 3, p. 310, doi. 10.1165/rcmb.2016-0428OC
- By:
- Publication type:
- Article
Anti-Inflammatory Effects of RTD-1 in a Murine Model of Chronic Pseudomonas aeruginosa Lung Infection: Inhibition of NF-κB, Inflammasome Gene Expression, and Pro-IL-1β Biosynthesis.
- Published in:
- Antibiotics (2079-6382), 2021, v. 10, n. 9, p. 1043, doi. 10.3390/antibiotics10091043
- By:
- Publication type:
- Article
Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
- Published in:
- 2016
- By:
- Publication type:
- journal article